Molecular Diagnosis & Therapy

, Volume 18, Issue 5, pp 505–522 | Cite as

Molecular Biomarkers in Interstitial Lung Diseases

Review Article

Abstract

Interstitial lung diseases (ILD) are protean conditions with substantial overlap in terms of diagnosis, prognostic evaluation, and management. However, the management of idiopathic pulmonary fibrosis is different from that of more immunologically driven ILD patterns, such as ILD associated with connective tissue diseases. It is important to provide accurate diagnosis and patient selection for prognostication and timely treatment, preferably at baseline. Validated non-invasive biomarkers fulfilling these unmet clinical needs are warranted. Although no ILD biomarker has been adopted in clinical practice so far, advancements in this field have been achieved, especially with the implementation of high-throughput techniques and clinical-laboratory multi-parametric panels. This review focuses on selected validated and/or potentially interesting biomarkers investigated in the peripheral blood and lung tissue of patients with ILD. Current issues and future directions in various aspects of ILD biomarkers research and its clinical application are explored.

References

  1. 1.
    de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8:53–82.PubMedGoogle Scholar
  2. 2.
    Wells AU. Histopathologic diagnosis in diffuse lung disease: an ailing gold standard. Am J Respir Crit Care Med. 2004;170:828–9.PubMedGoogle Scholar
  3. 3.
    Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42:750–7.PubMedGoogle Scholar
  4. 4.
    Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.PubMedGoogle Scholar
  5. 5.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.PubMedGoogle Scholar
  6. 6.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.PubMedGoogle Scholar
  7. 7.
    Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637.Google Scholar
  8. 8.
    Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol. 2009;21:636–41.PubMedGoogle Scholar
  9. 9.
    Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology (Oxford). 2007;46:442–5.Google Scholar
  10. 10.
    Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.PubMedGoogle Scholar
  11. 11.
    Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830–6.Google Scholar
  12. 12.
    Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology (Oxford). 2008;47 Suppl 5:v48–50.Google Scholar
  13. 13.
    Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531–7.Google Scholar
  14. 14.
    Wells AU. Pulmonary function tests in connective tissue disease. Semin Respir Crit Care Med. 2007;28:379–88.PubMedGoogle Scholar
  15. 15.
    Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543–8.Google Scholar
  16. 16.
    Jegal Y, Kim DS, Shim TS, Lim C-M, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639–44.PubMedGoogle Scholar
  17. 17.
    Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–42.PubMedGoogle Scholar
  18. 18.
    White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132:947–54.PubMedGoogle Scholar
  19. 19.
    Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88:470–6.PubMedGoogle Scholar
  20. 20.
    Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, König G, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med. 1996;154:400–6.PubMedGoogle Scholar
  21. 21.
    Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis. 1999;58:635–40.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Goh NSL, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56:2005–12.PubMedGoogle Scholar
  23. 23.
    Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177:91–8.PubMedPubMedCentralGoogle Scholar
  24. 24.
    B.D.W. Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.Google Scholar
  25. 25.
    Manolio T. Novel risk markers and clinical practice. N Engl J Med. 2003;349:1587–9.PubMedGoogle Scholar
  26. 26.
    Herazo-Maya JD, Kaminski N. Personalized medicine: applying “omics” to lung fibrosis. Biomark Med. 2012;6:529–40.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198–207.PubMedGoogle Scholar
  28. 28.
    Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004;125:522–6.PubMedGoogle Scholar
  29. 29.
    Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410–5.PubMedGoogle Scholar
  30. 30.
    Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162:2213–7.PubMedGoogle Scholar
  31. 31.
    Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172:488–93.PubMedGoogle Scholar
  32. 32.
    Walsh SLF, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69:216–22.PubMedGoogle Scholar
  33. 33.
    Wells AU, Desai SR, Rubens MB, Goh NSL, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.PubMedGoogle Scholar
  34. 34.
    Best AC, Meng J, Lynch AM, Bozic CM, Miller D, Grunwald GK, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology. 2008;246:935–40.PubMedGoogle Scholar
  35. 35.
    du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:459–66.PubMedGoogle Scholar
  36. 36.
    Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–90.PubMedGoogle Scholar
  37. 37.
    Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25:96–103.PubMedGoogle Scholar
  38. 38.
    Corte TJ, Wort SJ, Talbot S, Macdonald PM, Hansel DM, Polkey M, et al. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:41–50.PubMedGoogle Scholar
  39. 39.
    Corte TJ, Wort SJ, MacDonald PS, Edey A, Hansell DM, Renzoni E, et al. Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology. 2012;17:674–80.PubMedGoogle Scholar
  40. 40.
    Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J. 2010;36:819–25.PubMedGoogle Scholar
  41. 41.
    Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2004;170:360–5.PubMedGoogle Scholar
  42. 42.
    Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:650–6.PubMedGoogle Scholar
  43. 43.
    Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136:10–5.PubMedGoogle Scholar
  44. 44.
    Cottin V, Nunes H, Brillet P-Y, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–93.PubMedGoogle Scholar
  45. 45.
    Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234–40.PubMedGoogle Scholar
  46. 46.
    Park JH, Kim DS, Park I-N, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705–11.PubMedGoogle Scholar
  47. 47.
    Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.PubMedGoogle Scholar
  48. 48.
    Song J-W, Lee H-K, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:103–12.PubMedGoogle Scholar
  49. 49.
    Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–54.PubMedGoogle Scholar
  50. 50.
    du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med. 2012;186:712–5.PubMedGoogle Scholar
  51. 51.
    Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax. 2012;67:938–40.PubMedGoogle Scholar
  52. 52.
    Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow’s ear. Thorax. 2013;68:309–10.PubMedGoogle Scholar
  53. 53.
    King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014;189:825–31.PubMedGoogle Scholar
  54. 54.
    Hermans C, Bernard A. State of the art lung epithelium—specific proteins characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999;159:646–78.PubMedGoogle Scholar
  55. 55.
    Crandall ED, Kim KJ. Protein traffic across lung epithelia. Am J Respir Cell Mol Biol. 1989;1:255.PubMedGoogle Scholar
  56. 56.
    Collard HR, Calfee CS, Wolters PJ, Song JW, Hong S-B, Brady S, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299:L3–7.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148:637–42.PubMedGoogle Scholar
  58. 58.
    Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39:632–6.Google Scholar
  59. 59.
    Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589–97.PubMedGoogle Scholar
  60. 60.
    Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol. 2000;27:930–4.PubMedGoogle Scholar
  61. 61.
    Hant FN, Ludwicka-Bradley A, Wang H-J, Li N, Elashoff R, Tashkin DP, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36:773–80.PubMedGoogle Scholar
  62. 62.
    Bonella F, Volpe A, Caramaschi P, Nava C, Ferrari P, Schenk K, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:27–33.PubMedGoogle Scholar
  63. 63.
    Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol. 2003;21:429–36.PubMedGoogle Scholar
  64. 64.
    Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol. 2004;31:1112–20.PubMedGoogle Scholar
  65. 65.
    Sakamoto K, Taniguchi H, Kondoh Y, Johkoh T, Sumikawa H, Kimura T, et al. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respir Med. 2010;104:127–33.PubMedGoogle Scholar
  66. 66.
    Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429–34.PubMedGoogle Scholar
  67. 67.
    Hisata S, Kimura Y, Shibata N, Ono S, Kobayashi T, Chiba S, et al. A Normal range of KL-6/MUC1 independent of elevated SP-D indicates a better prognosis in the patients with honeycombing on high-resolution computed tomography. Pulm Med. 2011;2011:806014.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11:164–8.PubMedGoogle Scholar
  69. 69.
    Kida Y, Ohshimo S, Ota K, Tamura T, Otani T, Une K, et al. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome. Orphanet J Rare Dis. 2012;7:99.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Akihito Y, Nobuoki K, Hironobu H, Mitsunori S, Einosuke U, Keiichi K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1680–4.Google Scholar
  71. 71.
    Janssen R, Sato H, Grutters JC, Bernard A, van Velzen-Blad H, du Bois RM, et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest. 2003;124:2119–25.PubMedGoogle Scholar
  72. 72.
    Okada M, Suzuki K, Matsumoto M, Nakashima M, Nakanishi T, Takada K, et al. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases. Mod Rheumatol. 2007;17:131–6.PubMedGoogle Scholar
  73. 73.
    Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, Yoshioka K, et al. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir Med. 2012;106:1756–64.PubMedGoogle Scholar
  74. 74.
    Huang HB, Peng XN, Nakajima J. Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Biosci Trends. 2013;7:172–7.PubMedGoogle Scholar
  75. 75.
    Greene KE, King TE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19:439–46.PubMedGoogle Scholar
  76. 76.
    Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995;152:1860–6.PubMedGoogle Scholar
  77. 77.
    Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum. 2001;44:1363–9.PubMedGoogle Scholar
  78. 78.
    Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–81.PubMedGoogle Scholar
  79. 79.
    Daimon T, Tajima S, Oshikawa K, Bando M, Ohno S, Sugiyama Y. KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia. Intern Med. 2005;44:811–7.PubMedGoogle Scholar
  80. 80.
    Takahashi H, Imai Y, Fujishima T, Shiratori M, Murakami S, Chiba H, et al. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J. 2001;17:481–7.PubMedGoogle Scholar
  81. 81.
    Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax. 2003;58:52–7.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109–14.PubMedGoogle Scholar
  83. 83.
    Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med. 2000;162:258–63.PubMedGoogle Scholar
  84. 84.
    Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135:1557–63.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Horimasu Y, Hattori N, Ishikawa N, Tanaka S, Bonella F, Ohshimo S, et al. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms. BMC Med Genet. 2014;15:4.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Piotrowski WJ, Górski P, Pietras T, Fendler W, Szemraj J. The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit. 2011;17:CR598–607.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Nielsen KR, Steffensen R, Boegsted M, Baech J, Lundbye-Christensen S, Hetland ML, et al. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther. 2011;13:R109.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA. 2002;99:6292–7.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Cosgrove GP, Schwarz MI, Geraci MW, Brown KK, Worthen GS. Overexpression of matrix metalloproteinase-7 in pulmonary fibrosis. Chest. 2002;121:25S–6S.PubMedGoogle Scholar
  90. 90.
    Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:e93.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Vuorinen K, Myllärniemi M, Lammi L, Piirilä P, Rytilä P, Salmenkivi K, et al. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS. 2007;115:969–75.PubMedGoogle Scholar
  92. 92.
    Huh JW, Kim DS, Oh Y-M, Shim TS, Lim CM, Do Lee S, et al. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest. 2008;133:1101–6.PubMedGoogle Scholar
  93. 93.
    Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014;43:1430–8.PubMedGoogle Scholar
  94. 94.
    Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73:227–32.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol. 2000;119:203–9.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29:174–86.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Veraldi KL, Hsu E, Feghali-Bostwick CA. Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Curr Rheumatol Rep. 2010;12:19–25.PubMedGoogle Scholar
  98. 98.
    Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol. 2012;2012:121439.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med. 2014;35:181–200.PubMedGoogle Scholar
  100. 100.
    Feghali-Bostwick CA, Wilkes DS. Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena? Am J Respir Crit Care Med. 2011;183:692–3.PubMedGoogle Scholar
  101. 101.
    Moua T, Maldonado F, Decker PA, Daniels CE, Ryu JH. Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis. Mayo Clin Proc. 2014;89:319–26.PubMedGoogle Scholar
  102. 102.
    Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013;107:249–55.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Kang BH, Park JK, Roh JH, Song JW, Lee CK, Kim M, et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci. 2013;28:731–7.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Cottin V. Significance of connective tissue diseases features in pulmonary fibrosis. Eur Respir Rev. 2013;22:273–80.PubMedGoogle Scholar
  105. 105.
    Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140:1292–9.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380:689–98.PubMedGoogle Scholar
  107. 107.
    Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med. 2013;187:768–75.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol. 2013;191:2089–95.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;189:966–74.PubMedGoogle Scholar
  110. 110.
    Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One. 2010;5:e8959.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:717–23.PubMedGoogle Scholar
  112. 112.
    Tiev KP, Hua-Huy T, Kettaneh A, Gain M, Duong-Quy S, Tolédano C, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J. 2011;38:1355–60.PubMedGoogle Scholar
  113. 113.
    Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol. 2011;30:231–7.PubMedGoogle Scholar
  114. 114.
    Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998;25:308–13.PubMedGoogle Scholar
  115. 115.
    De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NSL, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40:435–46.PubMedGoogle Scholar
  116. 116.
    Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. Eur Respir Rev. 2013;22:552–7.PubMedGoogle Scholar
  117. 117.
    Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:588–94.PubMedGoogle Scholar
  118. 118.
    Fujiwara A, Kobayashi H, Masuya M, Maruyama M, Nakamura S, Ibata H, et al. Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases. Respirology. 2012;17:693–8.PubMedGoogle Scholar
  119. 119.
    Bournazos S, Fahim A, Hart SP. Identification of fibrocytes in peripheral blood. Am J Respir Crit Care Med. 2009;180:1279; author reply 1279.Google Scholar
  120. 120.
    Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005;2:e251.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Kadota J, Mizunoe S, Mito K, Mukae H, Yoshioka S, Kawakami K, et al. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med. 2005;99:111–7.PubMedGoogle Scholar
  122. 122.
    Oka S, Furukawa H, Shimada K, Hayakawa H, Fukui N, Tsuchiya N, et al. Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease. BMC Immunol. 2013;14:9.PubMedPubMedCentralGoogle Scholar
  123. 123.
    Lorenzen JM, Krämer R, Meier M, Werfel T, Wichmann K, Hoeper MM, et al. Osteopontin in the development of systemic sclerosis—relation to disease activity and organ manifestation. Rheumatology (Oxford). 2010;49:1989–91.Google Scholar
  124. 124.
    Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, Geraci MW, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med. 2004;170:242–51.PubMedGoogle Scholar
  125. 125.
    Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783–94.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006;173:188–98.PubMedPubMedCentralGoogle Scholar
  127. 127.
    Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One. 2009;4:e5134.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Lockstone HE, Sanderson S, Kulakova N, Baban D, Leonard A, Kok WL, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med. 2010;181:1367–75.PubMedGoogle Scholar
  129. 129.
    Christmann RB, Sampaio-Barros P, Stifano G, Borges CL, de Carvalho CR, Kairalla R, et al. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014;66:714–25.PubMedGoogle Scholar
  130. 130.
    Yang IV, Coldren CD, Leach SM, Seibold MA, Murphy E, Lin J, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax. 2013;68:1114–21.PubMedGoogle Scholar
  131. 131.
    Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma S-F, Tseng GC, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5:205ra136.PubMedGoogle Scholar
  132. 132.
    Yang IV, Luna LG, Cotter J, Talbert J, Leach SM, Kidd R, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One. 2012;7:e37708.PubMedPubMedCentralGoogle Scholar
  133. 133.
    van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370:433–43.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA. 2007;104:7552–7.PubMedPubMedCentralGoogle Scholar
  135. 135.
    Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:729–37.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2013;64:265–76.PubMedGoogle Scholar
  137. 137.
    Selman M, Lin H-M, Montaño M, Jenkins AL, Estrada A, Lin Z, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet. 2003;113:542–50.PubMedGoogle Scholar
  138. 138.
    Pantelidis P, Veeraraghavan S, du Bois RM. Surfactant gene polymorphisms and interstitial lung diseases. Respir Res. 2002;3:14.PubMedPubMedCentralGoogle Scholar
  139. 139.
    Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. 2008;45:654–6.PubMedGoogle Scholar
  140. 140.
    Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45:613–20.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503–12.PubMedPubMedCentralGoogle Scholar
  142. 142.
    Zhang Y, Noth I, Garcia JGN, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med. 2011;364:1576–7.PubMedGoogle Scholar
  143. 143.
    Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;189:770–8.PubMedGoogle Scholar
  144. 144.
    Stock CJ, Sato H, Fonseca C, Banya WAS, Molyneaux PL, Adamali H, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013;68:436–41.PubMedGoogle Scholar
  145. 145.
    Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest. 2012;142:1584–8.PubMedPubMedCentralGoogle Scholar
  146. 146.
    Peljto AL, Zhang Y, Fingerlin TE, Ma S-F, Garcia JGN, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232–9.PubMedGoogle Scholar
  147. 147.
    Plantier L, Crestani B, Wert SE, Dehoux M, Zweytick B, Guenther A, et al. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax. 2011;66:651–7.PubMedGoogle Scholar
  148. 148.
    Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1:309–17.PubMedPubMedCentralGoogle Scholar
  149. 149.
    Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–14.PubMedGoogle Scholar
  150. 150.
    Wells AU. The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev. 2010;19:237–41.PubMedGoogle Scholar
  151. 151.
    Baqir M, Vassallo R, Maldonado F, Yi ES, Ryu JH. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchol Interv Pulmonol. 2013;20:309–12.Google Scholar
  152. 152.
    De Santis M, Bosello SL, Peluso G, Pinnelli M, Alivernini S, Zizzo G, et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J. 2012;6:9–17.PubMedGoogle Scholar
  153. 153.
    Costabel U, Guzman J, Bonella F, Oshimo S. Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med. 2007;28:514–24.PubMedGoogle Scholar
  154. 154.
    Ikezoe K, Handa T, Mori K, Watanabe K, Tanizawa K, Aihara K, et al. Neutrophil gelatinase-associated lipocalin in idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(6):1807-9.Google Scholar
  155. 155.
    Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J. 1999;14:376–82.PubMedGoogle Scholar
  156. 156.
    Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:111–8.PubMedGoogle Scholar
  157. 157.
    Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med. 1994;149:655–9.PubMedGoogle Scholar
  158. 158.
    Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest. 2006;130:982–8.PubMedGoogle Scholar
  159. 159.
    Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J, et al. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol. 2009;69:268–74.PubMedGoogle Scholar
  160. 160.
    Phelps DS, Umstead TM, Mejia M, Carrillo G, Pardo A, Selman M. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest. 2004;125:617–25.PubMedGoogle Scholar
  161. 161.
    Hara A, Sakamoto N, Ishimatsu Y, Kakugawa T, Nakashima S, Hara S, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med. 2012;106:571–80.PubMedGoogle Scholar
  162. 162.
    Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, et al. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2000;162:1162–8.PubMedGoogle Scholar
  163. 163.
    Shinoda H, Tasaka S, Fujishima S, Yamasawa W, Miyamoto K, Nakano Y, et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration. 2009;78:285–92.PubMedGoogle Scholar
  164. 164.
    Sfriso P, Cozzi F, Oliviero F, Caso F, Cardarelli S, Facco M, et al. CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. Clin Exp Rheumatol. 2012;30:S71–5.PubMedGoogle Scholar
  165. 165.
    Yoshioka S, Mukae H, Sugiyama K, Kakugawa T, Sakamoto N, Nakayama S, et al. High-BAL fluid concentrations of RANTES in nonspecific interstitial pneumonia compared with usual interstitial pneumonia. Respir Med. 2004;98:945–51.PubMedGoogle Scholar
  166. 166.
    Walters EH, Gardiner PV. Bronchoalveolar lavage as a research tool. Thorax. 1991;46:613–8.PubMedPubMedCentralGoogle Scholar
  167. 167.
    Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J. 1999;14:245–8.PubMedGoogle Scholar
  168. 168.
    Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med. 2007;28:475–85.PubMedGoogle Scholar
  169. 169.
    Noël-Georis I, Bernard A, Falmagne P, Wattiez R. Database of bronchoalveolar lavage fluid proteins. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;771:221–36.PubMedGoogle Scholar
  170. 170.
    Wattiez R, Falmagne P. Proteomics of bronchoalveolar lavage fluid. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;815:169–78.PubMedGoogle Scholar
  171. 171.
    Landi C, Bargagli E, Bianchi L, Gagliardi A, Carleo A, Bennett D, et al. Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis. J Proteomics. 2013;83:60–75.PubMedGoogle Scholar
  172. 172.
    Wattiez R, Hermans C, Cruyt C, Bernard A, Falmagne P. Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases. Electrophoresis. 2000;21:2703–12.PubMedGoogle Scholar
  173. 173.
    Lindahl M, Ståhlbom B, Svartz J, Tagesson C. Protein patterns of human nasal and bronchoalveolar lavage fluids analyzed with two-dimensional gel electrophoresis. Electrophoresis. 1998;19:3222–9.PubMedGoogle Scholar
  174. 174.
    Shirahama R, Miyazaki Y, Okamoto T, Inase N, Yoshizawa Y. Proteome analysis of bronchoalveolar lavage fluid in lung fibrosis associated with systemic sclerosis. Allergol Int. 2010;59:409–15.PubMedGoogle Scholar
  175. 175.
    Okamoto T, Miyazaki Y, Shirahama R, Tamaoka M, Inase N. Proteome analysis of bronchoalveolar lavage fluid in chronic hypersensitivity pneumonitis. Allergol Int. 2012;61:83–92.PubMedGoogle Scholar
  176. 176.
    Hirsch J, Hansen KC, Burlingame AL, Matthay MA. Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1–23.PubMedGoogle Scholar
  177. 177.
    Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics. 2005;5:1423–30.PubMedGoogle Scholar
  178. 178.
    Willems S, Stijn W, Verleden SE, Vanaudenaerde BM, Wynants M, Marijke W, et al. Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Ann Thorac Med. 2013;8:38–45.PubMedGoogle Scholar
  179. 179.
    Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther. 2009;11:R111.PubMedPubMedCentralGoogle Scholar
  180. 180.
    Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26:414–20.PubMedGoogle Scholar
  181. 181.
    Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185:67–76.PubMedPubMedCentralGoogle Scholar
  182. 182.
    Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143:1422–9.PubMedGoogle Scholar
  183. 183.
    Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145:723–8.PubMedGoogle Scholar
  184. 184.
    Leng D, Huan C, Xie T, Liang J, Wang J, Dai H, et al. Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis. PLoS One. 2013;8:e71059.PubMedPubMedCentralGoogle Scholar
  185. 185.
    Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev. 2013;22:148–52.PubMedGoogle Scholar
  186. 186.
    Yokoyama A, Kohno N, Kondo K, Ueda S, Hirasawa Y, Watanabe K, et al. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Respirology. 1998;3:199–202.PubMedGoogle Scholar
  187. 187.
    Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005;52:2889–96.PubMedGoogle Scholar
  188. 188.
    Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007;56:1685–93.PubMedGoogle Scholar
  189. 189.
    Cai M, Bonella F, He X, Sixt SU, Sarria R, Guzman J, et al. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med. 2013;107:1444–52.PubMedGoogle Scholar
  190. 190.
    Elhaj M, Charles J, Pedroza C, Liu X, Zhou X, Estrada-Y-Martin RM, et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol. 2013;40:1114–20.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Honda Y. Clinical significance of serum surfactant proteins A and D in idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34(Suppl):181–5.PubMedGoogle Scholar
  192. 192.
    Moinzadeh P, Krieg T, Hellmich M, Brinckmann J, Neumann E, Müller-Ladner U, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol. 2011;20:770–3.PubMedGoogle Scholar
  193. 193.
    Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004;138:540–6.PubMedPubMedCentralGoogle Scholar
  194. 194.
    Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K, et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol. 1997;36:1270–5.PubMedGoogle Scholar
  195. 195.
    Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol. 1998;37:1188–92.PubMedGoogle Scholar
  196. 196.
    Takehara H, Tada S, Kataoka M, Matsuo K, Ueno Y, Ozaki S, et al. Intercellular adhesion molecule-1 in patients with idiopathic interstitial pneumonia. Acta Med Okayama. 2001;55:205–11.PubMedGoogle Scholar
  197. 197.
    Shijubo N, Imai K, Aoki S, Hirasawa M, Sugawara H, Koba H, et al. Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis. Clin Exp Immunol. 1992;89:58–62.PubMedPubMedCentralGoogle Scholar
  198. 198.
    Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki S, Ueno T, et al. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung. 2010;188:247–52.PubMedGoogle Scholar
  199. 199.
    Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4:R11.PubMedPubMedCentralGoogle Scholar
  200. 200.
    Simler NR. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax. 2004;59:581–5.PubMedPubMedCentralGoogle Scholar
  201. 201.
    Beirne P, Pantelidis P, Charles P, Wells AU, Abraham DJ, Denton CP, et al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J. 2009;34:1376–82.PubMedGoogle Scholar
  202. 202.
    Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis—a longitudinal study. Rheumatology (Oxford). 2008;47:45–9.Google Scholar
  203. 203.
    Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibros. Clin Exp Immunol. 1999;117:159–65.PubMedPubMedCentralGoogle Scholar
  204. 204.
    Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, et al. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2013;23:1076–84.PubMedGoogle Scholar
  205. 205.
    Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol. 2012;30:S44–9.PubMedGoogle Scholar
  206. 206.
    Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010;104:1204–10.PubMedGoogle Scholar
  207. 207.
    Korthagen NM, van Moorsel CHM, Barlo NP, Ruven HJT, Kruit A, Heron M, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011;105:106–13.PubMedGoogle Scholar
  208. 208.
    Nordenbaek C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol. 2005;34:293–7.PubMedGoogle Scholar
  209. 209.
    Kruit A, Grutters JC, Ruven HJT, van Moorsel CCM, van den Bosch JMM. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med. 2007;101:1563–71.PubMedGoogle Scholar
  210. 210.
    Alhamad EH, Cal JG, Shakoor Z, Almogren A, Alboukai AA. Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis. BMC Med Genet. 2013;14:66.PubMedPubMedCentralGoogle Scholar
  211. 211.
    Tsoutsou PG, Gourgoulianis KI, Petinaki E, Germenis A, Tsoutsou AG, Mpaka M, et al. Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis. Respir Med. 2006;100:938–45.PubMedGoogle Scholar
  212. 212.
    Tsoutsou PG, Gourgoulianis KI. Role of interleukin-10 in idiopathic pulmonary fibrosis. Eur Respir J. 2004;23:179–80; author reply 180.Google Scholar
  213. 213.
    Samukawa T, Hamada T, Uto H, Yanagi M, Tsukuya G, Nosaki T, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC Pulm Med. 2012;12:55.PubMedPubMedCentralGoogle Scholar
  214. 214.
    Rusanov V, Kramer MR, Raviv Y, Medalion B, Guber A, Shitrit D. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest. 2012;141:1047–54.PubMedGoogle Scholar
  215. 215.
    Ricci A, Mariotta S, Bronzetti E, Bruno P, Vismara L, De Dominicis C, et al. Serum CA 15-3 is increased in pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:54–63.PubMedGoogle Scholar
  216. 216.
    Takayama S, Kataoka N, Usui Y, Inase N, Natori Y, Nakayama M, et al. CA 19-9 in patients with benign pulmonary diseases. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28:1326–31.PubMedGoogle Scholar
  217. 217.
    Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9:1736–42.PubMedGoogle Scholar
  218. 218.
    Matusiewicz SP, Williamson IJ, Sime PJ, Brown PH, Wenham PR, Crompton GK, et al. Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis? Eur Respir J. 1993;6:1282–6.PubMedGoogle Scholar
  219. 219.
    Cobben NA, Drent M, Schols AM, Lamers RJ, Wouters EF, Van Dieijen-Visser MP. Serum lactate dehydrogenase and its isoenzyme pattern in ex-coalminers. Respir Med. 1997;91:616–23.PubMedGoogle Scholar
  220. 220.
    Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken). 2012;64:1405–14.Google Scholar
  221. 221.
    Plant MJ, Williams AL, O’Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:1473–7.PubMedGoogle Scholar
  222. 222.
    van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol. 1993;32(Suppl 3):9–13.PubMedGoogle Scholar
  223. 223.
    Marie I, Hachulla E, Chérin P, Dominique S, Hatron P-Y, Hellot M-F, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.PubMedGoogle Scholar
  224. 224.
    Lee SH, Shim HS, Cho SH, Kim SY, Lee SK, Son JY, et al. Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:102–12.PubMedGoogle Scholar
  225. 225.
    Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis. 2000;59:257–62.PubMedPubMedCentralGoogle Scholar
  226. 226.
    Tiev KP, Chatenoud L, Kettaneh A, Tolédano C, Bach J-F, Cabane J. Increase of CXCL10 serum level in systemic sclerosis interstitial pneumonia. La Rev Médecine Interne. 2009;30:942–6.Google Scholar
  227. 227.
    Fujita J. Hepatocyte growth factor and idiopathic pulmonary fibrosis. Chest. 1996;109:1413.PubMedGoogle Scholar
  228. 228.
    Yamanouchi H, Fujita J, Yoshinouchi T, Hojo S, Kamei T, Yamadori I, et al. Measurement of hepatocyte growth factor in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. Respir Med. 1998;92:273–8.PubMedGoogle Scholar
  229. 229.
    Chakraborty S, Chopra P, Hak A, Dastidar SG, Ray A. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs. 2013;22:499–515.PubMedGoogle Scholar
  230. 230.
    Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604–11.PubMedGoogle Scholar
  231. 231.
    Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984;11:663–5.PubMedGoogle Scholar
  232. 232.
    Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 2009;61:958–65.PubMedPubMedCentralGoogle Scholar
  233. 233.
    Jack CI, Jackson MJ, Johnston ID, Hind CR. Serum indicators of free radical activity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996;153:1918–23.PubMedGoogle Scholar
  234. 234.
    Rahman I, Skwarska E, Henry M, Davis M, O’Connor CM, FitzGerald MX, et al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med. 1999;27:60–8.PubMedGoogle Scholar
  235. 235.
    Malli F, Bardaka F, Tsilioni I, Karetsi E, Gourgoulianis KI, Daniil Z. 8-isoprostane levels in serum and bronchoalveolar lavage in idiopathic pulmonary fibrosis and sarcoidosis. Food Chem Toxicol. 2013;61:160–3.PubMedGoogle Scholar
  236. 236.
    Solans R, Motta C, Solá R, La Ville AE, Lima J, Simeón P, et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum. 2000;43:894–900.PubMedGoogle Scholar
  237. 237.
    Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;303:L1046–56.PubMedPubMedCentralGoogle Scholar
  238. 238.
    Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011;37:1119–27.PubMedGoogle Scholar
  239. 239.
    Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, et al. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol. 2013;168:717–25.PubMedGoogle Scholar
  240. 240.
    Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26(3):414–20.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Interstitial Lung Disease UnitRoyal Brompton HospitalLondonUK
  2. 2.Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental MedicineUniversity of ParmaParmaItaly

Personalised recommendations